Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1All patients in the study will be treated with ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
2Continued Ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
3OCR----1件: 13
4OCRELIZUMAB1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬3件: 13, 46, 49
5Ocrelizumab (CinnaGen, Iran)1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
6Ocrelizumab (Roche, Switzerland)1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
7Ocrelizumab / rhuMAb 2H71件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
8Ocrelizumab 300 mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
9Ocrelizumab 300mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
10Ocrelizumab 300mg /10ml1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
11Ocrelizumab 300mg/10 ml1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
12Ocrelizumab 300mg/10ml1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
13Ocrelizumab 500mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46
14Ocrelizumab 600 mg1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
15Ocrelizumab at home1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
16Ocrelizumab Dose 11件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
17Ocrelizumab Dose 2 and Dose 31件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
18Ocrelizumab IV1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
19Ocrelizumab SC1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
20Ocrelizumabu 200mg----1件: 46
21Ocrelizumabu 50mg----1件: 46
22OCREVUS1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
23Ocrevus 300 mg, solution à diluer pour perfusion1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
24Ocrrelizumab 300 mg----1件: 13
25Other: Observation of Ocrelizumab as Treatment in RRMS Patients1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
26Other: Ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
27Ovine Corticotropin-Releasing Hormone (oCRH)2件: Corticorelin,
Corticotropin
2件: D00146 ,
D03905
3件: CRHR1,
CRHR2,
MC2R 💬
6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75
28Short-course Ocrelizumab1件: Ocrelizumab1件: D05218 (Name: Ocrelizumab)1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13